UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

<u>February 18, 2016</u> (Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-11353	13-3757370
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
358 South Main Street,		
Burlington, North Carolina	27215	336-229-1127
(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

Summary information of the Company dated February 18, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS Registrant

By:

/s/ F. SAMUEL EBERTS III

F. Samuel Eberts III Chief Legal Officer and Secretary

February 18, 2016





8-K FILED FEBRUARY 18, 2016

1

This presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace, adverse actions of governmental and other third-party payers and the results from the Company's acquisition of Covance.

Actual results could differ materially from those suggested by these forwardlooking statements. Further information on potential factors that could affect LabCorp's operating and financial results is included in the Company's Form 10-K for the year ended December 31, 2014, and the Company's Form 10-Q for the quarter ended September 30, 2015, including under the heading risk factors, and in the Company's other filings with the SEC, as well as in the risk factors included in Covance's filings with the SEC. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.



LabCorp Diagnostics

The LabCorp Diagnostics segment includes historical LabCorp business units, excluding its Clinical Trials operations (which are part of the Covance Drug Development segment), and including the Nutritional Chemistry and Food Safety operations acquired as part of the Covance acquisition.

Covance Drug Development

2

The Covance Drug Development segment includes historical Covance business units, excluding its Nutritional Chemistry and Food Safety operations (which are part of the LabCorp Diagnostics segment), and including the LabCorp Clinical Trials operations.



The following consolidated results include Covance as of February 19, 2015; prior to February 19, 2015, all consolidated results exclude Covance

	<u>4Q15</u>	<u>4Q14</u>	% Change
Net Revenue	\$2,244.8	\$1,512.7	48.4%
Adjusted Operating Income ^{(1) (2)}	\$368.2	\$250.0	47.3%
Adjusted Operating Margin	<i>16.4%</i>	<i>16.5%</i>	(10 bps)
Adjusted EPS ^{(1) (2)}	\$1.98	\$1.65	20.0%
Operating Cash Flow	\$384.6	\$213.7	80.0%
Less: Capital Expenditures	(<u>\$85.1)</u>	(<u>\$46.3)</u>	(83.8%)
Free Cash Flow	\$299.5	\$167.4	78.9%

(1) Adjusted Operating Income and Adjusted EPS exclude amortization, restructuring and special items

(2) See Reconciliation of non-GAAP Financial Measures on slides 18 - 21



The following consolidated results include Covance as of February 19, 2015; prior to February 19, 2015, all consolidated results exclude Covance

	ve Months d 12/31/15	Twelve Months Ended 12/31/14	% Change
Net Revenue	\$8,505.7	\$6,011.6	41.5%
Adjusted Operating Income ^{(1) (2)}	\$1,446.9	\$1,028.3	40.7%
Adjusted Operating Margin	17.0%	17.1%	(10 bps)
Adjusted EPS ^{(1) (2)}	\$7.91	\$6.80	16.3%
Operating Cash Flow ⁽³⁾ Less: Capital Expenditures Free Cash Flow	\$982.4 (<u>\$255.8)</u> \$726.6	\$739.0 (<u>\$203.5)</u> \$535.5	32.9% (25.7%) 35.7%
Free Cash Flow, Excluding Acquisition-Related Charges ⁽⁴⁾	\$836.6	\$535.5	56.2%

(1) Adjusted Operating Income and Adjusted EPS exclude amortization, restructuring and special items

(2) See Reconciliation of non-GAAP Financial Measures on slides 18 - 21

4

(3) Operating cash flow is negatively impacted by approximately \$110 million of net non-recurring items related to the Covance acquisition

(4) Adjusted for approximately \$110 million of net non-recurring items related to the Covance acquisition



Pro forma results assume that the acquisition of Covance closed on January 1, 2014

	4Q15	<u>4Q14</u>	% Change
Net Revenue			
LabCorp Diagnostics	\$1,551.4	\$1,486.9	4.3%
Covance Drug Development	\$691.4	\$660.1	4.7%
Total Net Revenue	\$2,242.8	\$2,147.0	4.5%
Adjusted Operating Income ^{(1) (2)}			
LabCorp Diagnostics	\$293.3	\$273.3	7.3%
Adjusted Operating Margin	18.9%	18.4%	50 bps
Covance Drug Development	\$110.4	\$89.8	22.9%
Adjusted Operating Margin	16.0%	13.6%	240 bps
Unallocated Corporate Expense	(\$35.5)	(\$35.4)	<u>(0.3%)</u>
Total Adjusted Operating Income	\$368.2	\$327.7	12.4%
Total Adjusted Operating Margin	16.4%	15.3%	110 bps

(1) Adjusted Operating Income excludes amortization, restructuring and special items

(2) See Reconciliation of non-GAAP Financial Measures on slides 18 - 21

closed on Janua	ry 1, 2014	
		<u>% Change</u>
\$6,210.6	\$5,922.2	4.9%
\$2,628.7	\$2,610.5	0.7%
\$8,839.3	\$8,532.7	3.6%
) (2)		
\$1,239.8	\$1,129.4	9.8%
20.0%	19.1%	90 bps
\$371.5	\$340.3	9.2%
14.1%	13.0%	110 bps
se (\$134.1)	(\$136.4)	1.7%
ome \$1,477.2	\$1,333.3	10.8%
16.7%	15.6%	110 bps
	Twelve Months Ended 12/31/15 \$6,210.6 \$2,628.7 \$8,839.3 (2) \$1,239.8 20.0% \$371.5 14.1% se (\$134.1) ome \$1,477.2	$\begin{array}{c c} & \$2,628.7 & \$2,610.5 \\ \$8,839.3 & \$8,532.7 \\ & \$1,239.8 & \$1,129.4 \\ & 20.0\% & 19.1\% \\ & \$371.5 & \$340.3 \\ & 14.1\% & 13.0\% \\ & \$e & (\$134.1) & (\$136.4) \\ & \texttt{ome} & \$1,477.2 & \$1,333.3 \\ \end{array}$

Pro forma results assume that the acquisition of Covance closed on January 1, 2014

(1) Adjusted Operating Income excludes amortization, restructuring and special items

(2) See Reconciliation of non-GAAP Financial Measures on slides 18 - 21

The following consolidated results include Covance as of February 19, 2015; prior to February 19, 2015, all consolidated results exclude Covance

	<u>4Q14</u>	<u>1Q15</u>	<u>2Q15</u>	<u>3Q15</u>	<u>4Q15</u>
Total Depreciation	\$40.8	\$54.3	\$70.5	\$72.2	\$72.7
Total Amortization ⁽¹⁾	\$15.4	\$32.4	\$46.6	\$47.1	\$38.3
Total Adjusted EBITDA ⁽²⁾	\$295.1	\$360.1	\$463.4	\$460.0	\$443.6
Total Debt to Last Twelve Months Adjusted EBITDA ^{(2) (3)}	2.5x	4.2x	4.0x	3.8x	3.6x
Total Net Debt to Last Twelve Months Adjusted EBITDA ^{(2) (}	³⁾ 2.0x	3.9x	3.6x	3.4x	3.2x

(1) Excludes amortization of deferred financing fees

(2) Adjusted EBITDA excludes restructuring and special items

(3) Leverage ratios in 2015 include Covance Adjusted EBITDA from the twelve months prior to the relevant period on a pro forma basis

7

COVANCE DRUG DEVELOPMENT: SELECT FINANCIAL METRICS⁽¹⁾ (DOLLARS IN MILLIONS)

Backlog at 9/30/15	\$6,653
Fourth Quarter 2015 Covance Drug Development Net Revenue	(693)
Fourth Quarter 2015 Net Orders	816
Foreign Exchange Impact	(38)
Backlog at 12/31/15	\$6,738
Fourth Quarter 2015 Net Book-to-Bill	1.18
Trailing Twelve Month Net Book-to-Bill ⁽²⁾	1.23


(1) Does not tie due to rounding

8

(2) Assumes that the acquisition of Covance closed on January 1, 2015




FOURTH QUARTER 2015 NET REVENUE DISTRIBUTION



(1) Revenues recognized in over 30 currencies; the largest foreign currency accounts for less than 10% of total net revenue

2015 PRO FORMA NET REVENUE DISTRIBUTION

Pro forma results assume that the acquisition of Covance closed on January 1, 2015



(1) Revenues recognized in over 30 currencies; the largest foreign currency accounts for less than 10% of total net revenue

FOURTH QUARTER 2015 FOREIGN EXCHANGE IMPACT TO PRO FORMA NET REVENUE⁽¹⁾ (DOLLARS IN MILLIONS)

Pro forma results assume that the acquisition of Covance closed on January 1, 2014

	<u>Dollars</u>	Year over Year <u>% Growth</u>
<u>Consolidated</u>		
Net Revenue, as Reported Foreign Exchange Impact Net Revenue, Constant Currency	\$2,243 <u>\$27</u> \$2,270	4.5% <u>1.3%</u> 5.8%
LabCorp Diagnostics		
Net Revenue, as Reported Foreign Exchange Impact Net Revenue, Constant Currency	\$1,551 <u>\$12</u> \$1,563	4.3% <u>0.8%</u> 5.1%
Covance Drug Development		
Net Revenue, as Reported Foreign Exchange Impact Net Revenue, Constant Currency	\$691 <u>\$15</u> \$706	4.7% <u>2.3%</u> 7.0%

Does not tie due to rounding

Pro forma results assume that the acquisition of Covance closed on January 1, 2014

	<u>Dollars</u>	Year over Year <u>% Growth</u>
<u>Consolidated</u>		
Net Revenue, as Reported Foreign Exchange Impact	\$8,839 \$143	3.6% 1.7%
Net Revenue, Constant Currency	\$8,982	5.3%
LabCorp Diagnostics		
Net Revenue, as Reported	\$6,211	4.9%
Foreign Exchange Impact	\$48	0.8%
Net Revenue, Constant Currency	\$6,259	5.7%
Covance Drug Development		
Net Revenue, as Reported	\$2,629	0.7%
Foreign Exchange Impact	\$95	3.6%
Net Revenue, Constant Currency	\$2,723	4.3%

Does not tie due to rounding

2016 FINANCIAL GUIDANCE

Excluding the impact of amortization, restructuring and special items, guidance for 2016 is:

	Current Guidance (assumes foreign exchange rates effective as of January 31, 2016)
Total net revenue growth:	7.5% – 9.5% ⁽¹⁾
LabCorp Diagnostics net revenue growth:	3.5% – 5.5% ⁽²⁾
Covance Drug Development net revenue growth:	2% – 5% ⁽³⁾
Adjusted EPS:	\$8.45 - \$8.85
Free cash flow:	\$900 Million – \$950 Million

(1) Includes the impact from approximately 100 basis points of negative currency.

(2) Includes the impact from approximately 50 basis points of negative currency.
(3) Includes the impact from approximately 200 basis points of negative currency.



2014 PRO FORMA SEGMENT NET REVENUE RECONCILIATION (DOLLARS IN MILLIONS)

	<u>1Q14</u>	2Q14	<u>3Q14</u>	<u>4Q14</u>	<u>FY14</u>
LabCorp as reported	\$1,431	\$1,516	\$1,552	\$1,513	\$6,012
Adjustments ⁽¹⁾	(17)	(22)	(25)	(26)	(89)
LabCorp Diagnostics	\$1,414	\$1,494	\$1,527	\$1,487	\$5,922
Covance as reported	\$620	\$639	\$627	\$634	\$2,521
Adjustments ⁽²⁾	17	22	25	26	89
Covance Drug Development	\$637	\$661	\$652	\$660	\$2,610

(1) Adjustments include the removal of LabCorp's legacy clinical trial services business and the addition of Covance's nutritional chemistry and food safety business.

(2) Adjustments include the addition of LabCorp's legacy clinical trial services business and the removal of Covance's nutritional chemistry and food safety business.

2014 PRO FORMA SEGMENT RECONCILIATION

(DOLLARS IN MILLIONS)

	<u>1Q14</u>	<u>2Q14</u>	<u>3Q14</u>	<u>4Q14</u>	<u>FY14</u>
LabCorp Diagnostics Adjusted Operating Income, as reported	\$264.9	\$308.9	\$305.6	\$280.9	\$1,160.3
Adjustments ⁽¹⁾	(7.4)	(7.9)	(8.0)	(7.6)	(30.9)
LabCorp Diagnostics Adjusted Operating Income, revised	\$257.5	\$301.0	\$297.6	\$273.3	\$1,129.4
LabCorp Diagnostics Adjusted Operating Margin, revised	18.2%	20.1%	19.5%	18.4%	19.1%
Covance Drug Development Adjusted Operating Income, as reported	\$77.3	\$84.7	\$88.5	\$89.8	\$340.3
Adjustments					
Covance Drug Development Adjusted Operating Income, revised	\$77.3	\$84.7	\$88.5	\$89.8	\$340.3
Covance Drug Development Adjusted Operating Margin, revised	12.1%	12.8%	13.6%	13.6%	13.0%
Total Unallocated Corporate Expenses, as reported	\$39.3	\$41.9	\$43.1	\$43.0	\$167.3
Adjustments ⁽¹⁾	(7.4)	(7.9)	(8.0)	(7.6)	(30.9)
Total Unallocated Corporate Expenses, revised	\$31.9	\$34.0	\$35.1	\$35.4	\$136.4
Total Unallocated Corporate Expenses as a % of Total Net Revenue	1.6%	1.6%	1.6%	1.6%	1.6%

(1) During the fourth quarter of 2015, the Company refined its methodology for the calculation of unallocated corporate expenses, which impacts LabCorp Diagnostics Adjusted Segment Operating Income. The Company believes that this new allocation methodology better matches the corporate cost of services being consumed by the LabCorp Diagnostics segment. This methodology has been applied to prior periods for comparative purposes, as shown above.



2015 PRO FORMA SEGMENT RECONCILIATION

(DOLLARS IN MILLIONS)

16

	<u>1Q15</u>	<u>2Q15</u>	<u>3Q15</u>	<u>4Q15</u>	<u>FY15</u>
LabCorp Diagnostics Adjusted Operating Income, as reported	\$300.1	\$347.1	\$330.2		
Adjustments(1)	(10.4)	(10.1)	(10.4)		
LabCorp Diagnostics Adjusted Operating Income, revised	\$289.7	\$337.0	\$319.8	\$293.3	\$1,239.8
LabCorp Diagnostics Adjusted Operating Margin, revised	19.5%	21.4%	20.0%	18.9%	20.0%
Covance Drug Development Adjusted Operating Income, as reported	\$74.2	\$89.9	\$97.0		
Adjustments					
Covance Drug Development Adjusted Operating Income, revised	\$74.2	\$89.9	\$97.0	\$110.4	\$371.5
Covance Drug Development Adjusted Operating Margin, revised	11.9%	14.0%	14.5%	16.0%	14.1%
Total Unallocated Corporate Expenses, as reported	\$41.8	\$46.0	\$41.7		
Adjustments ⁽¹⁾	(10.4)	(10.1)	(10.4)		
Total Unallocated Corporate Expenses, revised	\$31.4	\$35.9	\$31.3	\$35.5	\$134.1
Total Unallocated Corporate Expenses as a % of Total Net Revenue	1.5%	1.6%	1.4%	1.6%	1.5%

(1) During the fourth quarter of 2015, the Company refined its methodology for the calculation of unallocated corporate expenses, which impacts LabCorp Diagnostics Adjusted Segment Operating Income. The Company believes that this new allocation methodology better matches the corporate cost of services being consumed by the LabCorp Diagnostics segment. This methodology has been applied to prior periods for comparative purposes, as shown above.

2014 PRO FORMA SEGMENT ADJUSTED OPERATING INCOME RECONCILIATION (DOLLARS IN MILLIONS)

LabCorp as reported	<u>1Q14</u> \$210.8	<u>2Q14</u> \$253.4	<u>3Q14</u> \$252.8	<u>4Q14</u> \$234.4	<u>FY14</u> \$951.4
Amortization	21.0	22.0	18.3	15.4	76.7
Adjustments ⁽¹⁾⁽²⁾	25.7	25.6	26.5	23.5	101.3
LabCorp Diagnostics ⁽²⁾	\$257.5	\$301.0	\$297.6	\$273.3	\$1,129.4
Covance as Reported	\$71.0	\$76.1	\$79.7	\$77.7	\$304.5
Adjustments ⁽³⁾	6.3	8.6	8.8	12.1	35.8
Covance Drug Development	\$77.3	\$84.7	\$88.5	\$89.8	\$340.3

(1) Adjustments include the removal of unallocated corporate expenses and LabCorp's legacy clinical trial services business, as well as the addition of Covance's nutritional chemistry and food safety business. Unallocated corporate expenses in 2014 were: Q1 (\$26.1 million), Q2 (\$27.6 million), Q3 (\$28.3 million), Q4 (\$27.5 million) and full-year (\$109.5 million).

(2) During the fourth quarter of 2015, the Company refined its methodology for the calculation of unallocated corporate expenses, which impacts LabCorp Diagnostics Adjusted Segment Operating Income. The Company believes that this new allocation methodology better matches the corporate cost of services being consumed by the LabCorp Diagnostics segment. This methodology has been applied to prior periods for comparative purposes, as shown above. Refer to slide 15 for additional detail.

(3) Adjustments include the removal of unallocated corporate expenses and Covance's nutritional chemistry and food safety business, as well as the addition of LabCorp's legacy clinical trial services business. Unallocated corporate expenses in 2014 were: Q1 (\$5.7 million), Q2 (\$6.4 million), Q3 (\$6.8 million), Q4 (\$7.8 million) and full-year (\$26.7 million).

LabCorp

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

The following consolidated results include Covance as of February 19, 2015; prior to February 19, 2015, all consolidated results exclude Covance

LABORATORY CORPORATION OF AMERICA HOLDINGS

Reconciliation of Non-GAAP Financial Measures

(in millions, except per share data)

	_	Three Months Ended December 31,				Twelve Months Ended December 31,			
Adjusted Operating Income		2015		2014		2015		2014	
Operating Income	\$	243.5	\$	219.0	\$	1,002.9	\$	910.4	
Acquisition-related costs		1.1		-		119.1		-	
Restructuring and other special charges		54.0		2.4		113.9		17.8	
Consulting fees and executive transition expenses		10.4		13.2		25.6		23.4	
Settlement costs		12.2		-		12.2		-	
Wind-down of minimum volume contract operations		5.7		-		5.7		-	
Project LaunchPad system implementation costs		3.0		-		3.0		-	
Amortization of intangibles and other assets		38.3		15.4		164.5		76.7	
Adjusted operating income	\$	368.2	\$	250.0	\$	1,446.9	\$	1,028.3	
Adjusted EPS									
Diluted earnings per common share	\$	1.11	\$	1.39	\$	4.34	\$	5.91	
Restructuring and special items		0.61		0.15		2.44		0.34	
Amortization expense		0.26		0.11		1.13		0.55	
Adjusted EPS	S	1.98	\$	1.65	\$	7.91	\$	6.80	

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

The following consolidated results include Covance as of February 19, 2015; prior to February 19, 2015, all consolidated results exclude Covance

LABORATORY CORPORATION OF AMERICA HOLDINGS Reconciliation of Non-GAAP Financial Measures

(in millions, except per share data)

	Three Months Ended December 31,				Twelve Months Ended December 31,				
Free Cash Flow:	h Flow: 2015		2014		2015		2014		
Net cash provided by operating activities	\$	384.6	\$	213.7	\$	982.4	\$	739.0	
Less: Capital expenditures		(85.1)		(46.3)		(255.8)		(203.5)	
Free cash flow	\$	299.5	\$	167.4	\$	726.6	\$	535.5	



RECONCILIATION OF NON-GAAP FINANCIAL MEASURES - FOOTNOTES

1) During the fourth quarter of 2015, the Company recorded net restructuring and special items of \$54.0 million. The charges included \$25.3 million in severance and other personnel costs along with \$17.0 million in facility-related costs associated with facility closures and general integration initiatives. A substantial portion of these costs relates to the planned closure of two Covance Drug Development segment ("CDD") operations that serviced a minimum volume contract that expired on October 31, 2015. In addition, the Company recorded asset impairments of \$11.9 million in unused facility-related costs. The Company incurred additional legal and other costs of \$5.7 million relating to the wind-down of the minimum volume contract operations. The Company also recorded \$10.1 million in consulting expenses relating to fees incurred as part of its Covance and \$0.3 million of accelerated equity compensation relating to the announced retirement of a Company executive (all recorded in selling, general and administrative expenses). During the fourth quarter, the Company paid \$12.2 million in settlement costs and litigation expenses related to the resolution of a declerated with the implementation of a major system as part of its Project LaunchPad business process improvement initiative. The after tax impact of these charges decreased net earnings for the quarter ended December 31, 2015, by \$63.2 million and diluted earnings per share by \$0.61 (\$63.2 million divided by 103.2 million shares).

During the first three quarters of 2015, the Company recorded net restructuring and other special charges of \$59.9 million. The charges included \$33.9 million in severance and other personnel costs along with \$12.1 million in costs associated with facility closures and general integration initiatives. The Company reversed previously established reserves of \$0.9 million in unused facility-related costs. In addition, the Company recorded asset impairments of \$14.8 million relating to lab and customer service applications that will no longer be used. The Company also recorded \$15.3 million of consulting expenses relating to fees incurred as part of Project LaunchPad as well as Covance integration costs, along with \$4.3 million in short-term equity retention arrangements relating to the acquisition of Covance (all recorded in selling, general and administrative expenses). In addition, the Company recorded a non-cash loss of \$2.3 million, upon the dissolution of one of its equity investments (recorded in other, net in the accompanying Consolidated Statements of Operations).

During the first quarter of 2015, the Company recorded \$166.0 million of one-time costs associated with its acquisition of Covance. The costs included \$79.5 million of Covance employee equity awards, change in control payments and short-term retention arrangements that were accelerated or triggered by the acquisition transaction (recorded in selling, general and administrative expenses in the accompanying Consolidated Statements of Operations). The acquisition costs also included advisor and legal fees of \$33.9 million (recorded in selling, general and administrative expenses in the accompanying Consolidated Statements of Operations), \$15.2 million of deferred financing fees associated with the Company's bridge loan facility as well as a make-whole payment of \$37.4 million paid to call Covance's private placement debt outstanding at the purchase date (both amounts recorded in interest expense in the accompanying Consolidated Statements of Operations).

The after tax impact of these charges decreased net earnings for the twelve months ended December 31, 2015, by \$245.7 million and diluted earnings per share by \$2.44 (\$245.7 million divided by 100.6 million shares).

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES - FOOTNOTES

2) During the fourth quarter of 2014, the Company recorded net restructuring and special items of \$2.4 million. The charges included \$0.7 million in severance and other personnel costs along with \$1.7 million in facility-related costs associated with facility closures and general integration initiatives.

In addition to these net restructuring charges, the Company recorded \$13.2 million in consulting expenses relating to fees incurred as part of Project LaunchPad as well as legal fees associated with its Covance, Inc. acquisition (all such fees are recorded in selling, general and administrative).

In conjunction with the financing of the Covance transaction, the Company incurred \$4.7 million in bridge financing fees and wrote-off \$1.3 million in deferred financing costs relating to its prior credit agreement which was replaced with a new credit facility. These Covance-related financing costs are recorded in interest expense.

The after tax impact of these combined charges decreased net earnings for the three months ended December 31, 2014, by \$13.3 million and diluted earnings per share by \$0.15 (\$13.3 million divided by 86.3 million shares).

During the first three quarters of 2014, the Company recorded net restructuring and special items of \$15.4 million. The charges included \$9.9 million in severance and other personnel costs along with \$6.6 million in costs associated with facility closures and general integration initiatives. The Company reversed previously established reserves of \$0.4 million in unused severance and \$0.7 million in unused facility-related costs. In addition, the Company recorded \$10.1 million in consulting expenses relating to fees incurred as part of Project LaunchPad as well as legal fees associated with its LipoScience acquisition and one-time CFO transition costs (all such fees are recorded in selling, general and administrative). The after tax impact of these combined charges decreased net earnings for the year ended December 31, 2014, by \$29.1 million and diluted earnings per share by \$0.34 (\$29.1 million divided by 86.4 million shares).

3) The Company continues to grow the business through acquisitions and uses Adjusted EPS Excluding Amortization as a measure of operational performance, growth and shareholder returns. The Company believes adjusting EPS for amortization provides investors with better insight into the operating performance of the business. For the quarters ended December 31, 2015 and 2014, intangible amortization was \$38.3 million and \$15.4 million, respectively (\$26.9 million and \$9.5 million net of tax, respectively) and decreased EPS by \$0.26 (\$26.9 million divided by 103.2 million shares) and \$0.11 (\$9.5 million divided by 86.2 million shares), respectively. For the twelve months ended December 31, 2015 and 2014, intangible amortization was \$164.5 million and \$76.7 million, respectively (\$113.5 million and \$47.3 million net of tax, respectively) and decreased EPS by \$1.13 (\$113.5 million divided by 100.6 million shares) and \$0.55 (\$47.3 million divided by 86.4 million shares), respectively.

